Table 2. Individual effects of inflammatory markers and FGF23 on all-cause mortality.
For each exposure, results are presented per 1 standard deviation (SD) increase in the overall population and according to quartiles.
| Hazard Ratio (95% Confidence Interval) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (total) | N (events) | Unadjusted | P* | Model A | P* | Model B | P* | Model C | P* | |
| IL-6 | ||||||||||
| Per 1 SD lnIL-6 | 3875 | 550 | 1.52 (1.43–1.61) | < .0001 | 1.38 (1.28–1.49) | < .0001 | 1.38 (1.28–1.48) | < .0001 | 1.35 (1.25–1.46) | < .0001 |
| Quartile 1 ≤ 1.2 | 970 | 64 | Reference | < .0001 | Reference | < .0001 | Reference | < .0001 | Reference | < .0001 |
| Quartile 2 ≤ 1.9 | 968 | 113 | 2.03 (1.49–2.75) | 1.43 (1.04–1.97) | 1.39 (1.01–1.92) | 1.34 (0.97–1.85) | ||||
| Quartile 3 ≤ 3.2 | 969 | 145 | 2.80 (2.08–3.75) | 1.74 (1.28–2.37) | 1.73 (1.27–2.36) | 1.69 (1.24–2.31) | ||||
| Quartile 4 ≤ 3.2 | 968 | 228 | 5.00 (3.79–6.60) | 2.93 (2.17–3.95) | 2.83 (2.09–3.83) | 2.65 (1.95–3.60) | ||||
| CRP | ||||||||||
| Per 1 SD lnCRP | 3873 | 550 | 1.39 (1.27–1.51) | < .0001 | 1.31 (1.19–1.43) | < .0001 | 1.28 (1.17–1.40) | < .0001 | 1.28 (1.16–1.40) | < .0001 |
| Quartile 1 ≤ 1.1 | 974 | 91 | Reference | < .0001 | Reference | < .0001 | Reference | < .0001 | Reference | < .0001 |
| Quartile 2 ≤ 2.6 | 965 | 115 | 1.26 (0.96–1.66) | 1.18 (0.90–1.57) | 1.19 (0.90–1.58) | 1.20 (0.90–1.59) | ||||
| Quartile 3 ≤ 6.5 | 969 | 154 | 1.71 (1.32–2.21) | 1.57 (1.20–2.04) | 1.53 (1.17–2.00) | 1.51 (1.15–1.97) | ||||
| Quartile 4 >6.5 | 965 | 190 | 2.25 (1.75–2.89) | 1.97 (1.51–2.56) | 1.87 (1.43–2.44) | 1.89 (1.44–2.48) | ||||
| FGF23 | ||||||||||
| Per 1 SD lnFGF23 | 3875 | 550 | 1.64 (1.53–1.76) | < .0001 | 1.53 (1.40–1.67) | < .0001 | 1.51 (1.38–1.65) | < .0001 | 1.45 (1.32–1.60) | < .0001 |
| Quartile 1 ≤ 95.8 | 969 | 83 | Reference | < .0001 | Reference | < .0001 | Reference | < .0001 | Reference | < .0001 |
| Quartile 2 ≤ 145.6 | 969 | 107 | 1.41 (1.06–1.88) | 1.17 (0.87–1.57) | 1.16 (0.86–1.57) | 1.15 (0.84–1.56) | ||||
| Quartile 3 ≤239.3 | 969 | 146 | 2.25 (1.72–2.95) | 1.63 (1.22–2.19) | 1.65 (1.23–2.22) | 1.54 (1.14–2.09) | ||||
| Quartile 4>239.3 | 968 | 214 | 4.21 (3.26–5.43) | 2.84 (2.11–3.82) | 2.79 (2.07–3.77) | 2.48 (1.81–3.39) | ||||
Model A: Stratified by site and adjusted for age, sex, race, ethnicity, body mass index, diabetes, smoking status, history of cardiovascular disease, systolic blood pressure, estimated glomerular filtration rate, urine albumin-to-creatinine ratio categories, serum albumin, hemoglobin, low-density lipoprotein
Model B: Model A plus use of use of aspirin, beta blockers, statins, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, active vitamin D, nutritional vitamin D, phosphate binders, and steroids.
Model C: Model B plus serum calcium, phosphate and parathyroid hormone.
For quartile analyses, p values correspond to tests for linear trend
IL-6, interleukin-6; CRP, high-sensitivity C-reactive protein; SD, standard deviation